Project Grant R01HL171094
Award Date
7/15/24
Completion Date
5/31/28
Dollars Obligated
$2.1M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Newark, NJ 07107, USA
Similar Awards
This federal Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), provides $2,282,515.00 to The University of Texas Southwestern Medical Center to develop non-invasive imaging biomarkers for detecting early metabolic changes associated with muscular dystrophy and cardiomyopathy. The award, effective June 15, 2024 through April 30, 2028, aims to leverage hyperpolarized carbon-13 MRI to assess...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,408,580 Project Grant under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) to The Leland Stanford Junior University. The grant, titled "Evaluation of the AMPK-BACH1-NRF2 Axis as a Therapeutic Target for Inherited DCM", aims to explore the potential of activating the AMPK-BACH1-NRF2 signaling pathway as a treatment for inherited forms of dilated cardiomyopathy (DCM), a leading cause of heart...
This federal Project Grant award, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to develop improved gene therapy approaches for treating Duchenne muscular dystrophy (DMD). The $671,240 award, which runs from January 2025 to December 2029, will fund research at the University of Washington to refine technologies for expressing larger and more functional...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $1,358,179 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Revidia Therapeutics, Inc. to conduct IND-enabling safety and toxicity testing of a subcutaneous formulation of the PTP1B inhibitor MSI-1436. This novel small molecule therapy aims to treat fatal cardiomyopathy in patients with Duchenne muscular dystrophy (DMD), a rare and debilitating genetic...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), will provide $610,819 to Duke University to conduct research focused on optimizing gene therapy for respiratory insufficiency in Duchenne muscular dystrophy (DMD). The researchers will comprehensively examine breathing and respiratory motor units in novel humanized mouse models of DMD, define the impact of dystrophin deficiency on...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $171,811 to The Johns Hopkins University to conduct a 5-year research project on the role of skeletal muscle actin mutations in dilated cardiomyopathy (DCM). The key objectives are to: 1) define the mechanistic basis of how skeletal muscle actin mutations, specifically the R256H mutation, contribute to DCM, and 2) support the Principal...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $159,512 to The Leland Stanford Junior University to conduct research aimed at uncovering effective strategies to mitigate the detrimental effects of cardiac fibrosis in diseases like dilated cardiomyopathy (DCM). The key focus is to validate and describe the anti-fibrotic mechanisms of two previously identified drug compounds,...
This federal Project Grant award, totaling $1,981,854.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The funding will support research at Loyola University of Chicago's Health Sciences Campus to investigate the structural and functional basis of myocardial dysregulation in genetic cardiomyopathies. Specifically, the researchers will use advanced techniques like synchrotron X-ray diffraction and mass...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research to investigate the role of the unfolded protein response (UPR) in genetic dilated cardiomyopathy (DCM). The $159,512 award, spanning Sep 30, 2024 to Jan 29, 2026, will utilize induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) carrying DCM mutations to study the cellular and molecular mechanisms linking ER...
The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $736,574 Project Grant (R01HL175488) to the Icahn School of Medicine at Mount Sinai (ISMMS) to investigate the role of the RNA-binding protein DDX3X in heart development and disease. The grant, which runs from July 1, 2024 to June 30, 2028, is funded under the NHLBI's Cardiovascular Diseases Research program (CFDA 93.837). The research aims to uncover the direct and functionally relevant targets of DDX3X, determine the...